Transdermal Diagnostics: non-invasive, affordable, continuous glucose monitoring for diabetes management and prevention.

透皮诊断：用于糖尿病管理和预防的非侵入性、经济实惠的连续血糖监测。

• 批准号: 10027343
• 金额: $ 37.97万
• 依托单位: TRANSDERMAL DIAGNOSTICS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10027343
• 关键词: Transdermal; Diagnostics; non; invasive; affordable

Diabetes is a huge, global health problem and a significant economic burden on the NHS and other healthcare systems. Worldwide, over 460M people have diabetes and 10% of these are Type I and need insulin injections to control the amount of sugar (specifically, glucose) in their blood. The (growing) majority, however, live with Type 2 diabetes and are not, at least in the earlier stages of the disease, insulin-dependent. Furthermore, there are nearly 380M adults with prediabetes but only ~15% have been diagnosed. Close monitoring and control of blood glucose levels is therefore a major medical priority in the management of diabetes.The very expensive continuous glucose monitoring (CGM) devices presently on the market are aimed at Type 1s undergoing intensive treatment with insulin and involve implantation of a small needle or fibre under the skin and long-term wear. In contrast, Type 2s, people with prediabetes and Type 1s without access to these CGMs rely almost exclusively on infrequent and unpleasant "fingerpricking" to monitor their blood sugar and do so, unsurprisingly, with reluctance, resulting in very poor control of their glucose levels. The potential market for a non-invasive and needle-free, technology in this significant and growing sector of diabetic healthcare is therefore clear.This project aims to develop the first truly needle- and calibration-free monitor for CGM that is low-cost and widely accessible as a result. Our monitor specifically accesses hair follicles to extract a very small volume of the fluid which bathes the living cells in the skin. This fluid contains glucose at a level which is very similar to that in the blood. Our game-changing approach, therefore, is an affordable device that communicates with a mobile phone via a customised app - all within a wearable patch, with disposable components. The goal is a discreet, affordable and user-friendly device for people with diabetes that significantly slows down, or even prevents, the progression of their condition and enables blood glucose levels to be monitored and controlled in a completely painless manner.

糖尿病是一个巨大的全球性健康问题，也是NHS和其他医疗保健系统的重大经济负担。在全球范围内，超过4.6亿人患有糖尿病，其中10%是I型糖尿病，需要注射胰岛素来控制血液中的糖（特别是葡萄糖）含量。然而，大多数人患有2型糖尿病，并且至少在疾病的早期阶段不依赖胰岛素。此外，有近3.8亿成年人患有前驱糖尿病，但只有约15%被诊断出来。因此，密切监测和控制血糖水平是糖尿病管理中的主要医疗优先事项。目前市场上非常昂贵的连续葡萄糖监测（CGM）设备针对的是正在接受胰岛素强化治疗的1型糖尿病患者，并且涉及在皮肤下植入小针或纤维并长期佩戴。相比之下，2型糖尿病患者，患有前驱糖尿病的人和无法获得这些CGMs的1型糖尿病患者几乎完全依赖于不频繁和不愉快的“手指刺”来监测他们的血糖，并且毫不奇怪，不情愿地这样做，导致他们的血糖水平控制非常差。因此，在糖尿病医疗保健这一重要且不断增长的领域，无创和无针技术的潜在市场是显而易见的。该项目旨在开发第一个真正的无针和无校准CGM监测仪，该监测仪成本低，因此可广泛使用。我们的监测仪专门进入毛囊，提取非常少量的液体，这些液体浸泡在皮肤中的活细胞中。这种液体所含的葡萄糖水平与血液中的葡萄糖水平非常相似。因此，我们改变游戏规则的方法是一种经济实惠的设备，通过定制的应用程序与移动的手机通信-所有这些都在可穿戴贴片中，使用一次性组件。我们的目标是为糖尿病患者提供一种谨慎，负担得起和用户友好的设备，可以显着减缓甚至阻止病情的进展，并能够以完全无痛的方式监测和控制血糖水平。